Alfa Wassermann   Report issue

For profit Phase 2 Phase 3
Founded: West Caldwell NJ United States (1960)
Status: No NME R&D (1960)

Organization Overview

First Clinical Trial
2002
NCT00732927
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Alfa Wassermann, Bologna, Italy | Alfa Wassermann S.p.A. | Alfa Wassermann Tunisia

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Arterial Occlusive Diseases (Phase 3)

Ascites (Phase 3)

Crohn Disease (Phase 2)

Gastroparesis (Phase 2)

Kidney Diseases (Phase 3)

Peritonitis (Phase 3)

Renal Insufficiency, Chronic (Phase 3)

Retinal Vein Occlusion (Phase 3)

Vaginal Diseases (Phase 2)

Vaginosis, Bacterial (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 9
  • # of Trial APIs: 11